Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention.
about
Biomarkers and surrogate endpointsOvercoming Challenges With Statin TherapyControl of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey.Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic model.A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study.Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in FinlandEffectiveness of an intervention designed to optimize statins use: a primary prevention randomized clinical trialAdherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort studyImplementation of patient education at first and second dispensing of statins in Dutch community pharmacies: the sequel of a cluster randomized trialThe impact of statins on biological characteristics of stem cells provides a novel explanation for their pleiotropic beneficial and adverse clinical effects.Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study.Statin prescription patterns, adherence, and attainment of cholesterol treatment goals in routine clinical care: a Danish population-based study.Implementing a statin switching programme in primary care: patients' views and experiences.Educational Level, Anticoagulation Quality, and Clinical Outcomes in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study.Predictors of nonadherence to statins: a systematic review and meta-analysis.Persistence with statin therapy in Hungary.Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: resolved and unresolved issues.Driving forces behind increasing cardiovascular drug utilization: a dynamic pharmacoepidemiological model.Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular riskPredictors of first-year statin medication discontinuation: A cohort study.Comparison of diet quality, physical activity and biochemical values of older adults either reporting or not reporting use of lipid-lowering medicationTherapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a 'real-world' retrospective cohort study.Non-adherence to statin therapy: a major challenge for preventive cardiology.Dynamics of long-term statin therapy.Use of principal component analysis in the evaluation of adherence to statin treatment: a method to determine a potential target population for public health intervention.Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.A systematic review to assess adherence and persistence with statins.Can We Identify Minority Patients at Risk of Nonadherence to Antiplatelet Medication at the Time of Coronary Stent Placement?Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence.A simple informative intervention in primary care increases statin adherence.Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice.Strategies to improve adherence with medications in chronic, 'silent' diseases representing high cardiovascular risk.Adherence to preventive statin therapy according to socioeconomic position.The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.Estimates of statin discontinuation rates are influenced by exposure and outcome definitions.Healthcare Utilization and Statin Re-Initiation Among Medicare Beneficiaries With a History of Myocardial Infarction.
P2860
Q24678760-9FEC7048-1768-482A-B1E4-37D98D8FA1CFQ28073319-9C226ADC-66FD-4D8C-9FFF-034C29FACE9CQ30843700-84FF36E6-8173-4AF4-8D2D-8191989CF1EFQ33569145-967125A6-8639-40A6-89AA-2BA5A471D020Q33743492-F4CD85BC-278D-49BE-8C36-614A332B8DB7Q33795544-08658A77-9EB6-4E80-8B22-2B55AA53681DQ33957577-1B228BC1-9F0D-436D-92BB-1C41E6FAD74BQ33972105-8DBD527C-8743-4B2A-878C-66594E3D2776Q34075903-B6D0FF2E-FE6C-43A9-B8C6-E40C24CAC433Q34671958-1017675C-5C64-46B0-AEEE-B8430AC28CEAQ34976504-80D07F59-B012-4950-9E59-E153484F14B9Q35135911-5504C834-2437-44C6-BF0D-0A61F039E78CQ36087995-129B3467-C070-4BB2-ACFD-23983508BB0EQ36126175-B733E31F-2530-4180-9328-F9B61A7966A0Q36809178-300E0158-FDA2-4A0C-ACD9-24BBDE7FDD69Q36984006-1372FB9A-9CD8-4884-BAD0-C7D34099370EQ37100610-EBEB7D3D-3668-4877-A82C-69B91AF00DF1Q37175807-4639C92C-9447-48D7-9EB3-212DAF74A377Q37202135-C3BFEE23-6099-478C-B1AC-425CD9ACFE0BQ37235293-923249D4-4713-4174-8BBA-D0BCC2FDF755Q37320254-41B1E8DA-3A3E-4C76-8758-38A0A2BA97C1Q37454789-75DC7A2C-574E-4CE4-89F8-EB05C1D36E66Q37642755-777F02F5-EDB6-4C33-8462-FCF0226A1F9BQ37853479-188AE7AB-A629-4600-8AA7-E27258A6C6ABQ37897661-5CE7FAC6-8572-4624-AABF-3B0259281422Q38379459-56DA7D69-7C75-499F-A75C-AAEE5F29BB16Q39026831-177E4D93-6648-49B0-84B9-B9100BB1C3B7Q39036157-AB0361EA-A468-4783-80DE-1BB961CB7B32Q40208462-F26E9A89-AEB0-4256-A53E-7969A2D816E0Q40327063-D884AFD1-980D-41BC-A84D-2D711160CA29Q41301852-7CA2CCC7-F321-47A1-B860-D02B7060CE91Q43042777-D90EB49D-E157-4E60-B911-41669B4B56C4Q44003644-2B712590-1AD5-466D-85EF-B18305791A83Q44047476-3E97CD9A-61CF-4977-A3C9-64EDFCBE9170Q45048699-C6DC94E2-2295-41CD-AC8C-AFF98F7926AEQ55413700-3D548F01-E5A2-4952-AF89-F76AC8ACFE21
P2860
Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Persistence and determinants o ...... mary and secondary prevention.
@ast
Persistence and determinants o ...... mary and secondary prevention.
@en
type
label
Persistence and determinants o ...... mary and secondary prevention.
@ast
Persistence and determinants o ...... mary and secondary prevention.
@en
prefLabel
Persistence and determinants o ...... mary and secondary prevention.
@ast
Persistence and determinants o ...... mary and secondary prevention.
@en
P2093
P2860
P1476
Persistence and determinants o ...... mary and secondary prevention.
@en
P2093
A Dragomir
D Berbiche
F St-Maurice
S Perreault
P2860
P304
P356
10.1111/J.1365-2125.2005.02355.X
P407
P577
2005-05-01T00:00:00Z